Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

ABSTRACT:

Importance

One in 6 American men will be diagnosed as having prostate cancer during their lifetime. Although there are no data to support the use of primary androgen-deprivation therapy (ADT) for early-stage prostate cancer, primary ADT has been widely used for localized prostate cancer, especially among older patients.

Objective

To determine the long-term survival impact of primary ADT in older men with localized (T1/T2) prostate cancer.

Design, setting, and participants

This was a population-based cohort study of 66,717 Medicare patients 66 years or older diagnosed from 1992 through 2009 who received no definitive local therapy within 180 days of prostate cancer diagnosis. The study was conducted in predefined US geographical areas covered by the Surveillance, Epide

SUBMITTER: Lu-Yao GL 

PROVIDER: S-EPMC5499229 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature